Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Sponsor

Delcath Systems Inc.

United States 566 Queensbury Avenue, 12804, United States

About the sponsor

Clinical research in refractory metastatic colorectal cancer with liver-dominant disease focuses on treatments aimed at controlling tumour growth in the liver and limiting hepatic progression.

  • Hepatic progression-free survival
  • Bevacizumab
  • Trifluridine-tipiracil

The therapeutic interest centres on advanced gastrointestinal oncology and disease control in patients with limited options after prior treatment.

About Specializations

Delcath Systems Inc. runs clinical trials in conditions such as Breast cancer metastatic, Colorectal cancer metastatic, Colorectal cancer, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

2 clinical trials

Breast cancer metastatic

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Delcath Systems Inc.

Colorectal cancer metastatic+1

Recruiting
Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Delcath Systems Inc.

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.